Project Grant HT94252410768
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$630K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $472,500.00 to the University of California, Los Angeles (UCLA) for the development of a next-generation, off-the-shelf CAR-NKT cell therapy for metastatic clear cell renal cell carcinoma. The award, with a period of performance from September 15, 2024 to September 14, 2026, supports advanced biomedical research focused on transforming...
This federal Project Grant award for $708,750.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a next-generation, off-the-shelf CAR-NKT cell therapy for the treatment of metastatic clear cell renal cell carcinoma. The award was granted to the University of California, Los Angeles (UCLA) on September 15, 2024, with a project period ending on September 14, 2026. This research aims to advance...
The University of California, Los Angeles (UCLA) has been awarded a $626,081 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The grant, titled "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance," will support advanced biomedical research to transform healthcare for military service members and the broader public. The research...
The University of California, Los Angeles (UCLA) was awarded a $472,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program, administered by the Defense Health Agency. The grant, titled "Targeting TROP2-Mediated Ferroptosis as a New Therapy for Advanced Prostate Cancer," aims to advance biomedical research focused on transforming healthcare for military service members and the general public. The award, effective May 1, 2025, with a completion date...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,312,000.00 to The Regents of the University of California, San Francisco to conduct research on strategies to upregulate and image Nectin4 to enhance Nectin4-targeted therapies in bladder cancer. The award period runs from August 1, 2025 to July 31, 2029. The goal of this research is to advance scientific understanding and develop potential...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
This Project Grant award in the amount of $644,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The funding supports research by the University of California, Davis on a PLZ4-targeting ultra-small DM1 nanoconjugate for bladder cancer therapy. The award has a performance period from June 1, 2025 to May 31, 2027, with the goal of advancing innovative medical solutions and transforming healthcare for military...
The Defense Health Agency has awarded a $893,000 Project Grant to the University of California, Los Angeles (UCLA) - Office of Research Administration to conduct research under the Military Medical Research and Development program (CFDA 12.420). This four-year grant, effective August 15, 2023 through August 14, 2027, will support UCLA's efforts to investigate the EGFR signaling network in glioblastoma, an aggressive form of brain cancer. As the prime grantee, UCLA will leverage its research...
The U.S. Department of Defense's Defense Health Agency awarded a $1,037,990 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) to develop a safe small molecule approach to prevent kidney cancer metastasis. The three-year grant, which began on September 1, 2023, will support UCLA's research efforts to investigate new treatments for kidney cancer that could benefit military service members and the general...